Seven cases were reclassified as high-grade B-cell lymphoma with translocations of MYC and BCL2...113 patients (62.8%) received rituximab-chemotherapy (median 5 cycles, IQR = 4-6 with R-CHOP for n = 92 [81.4%]) followed by RT...There was a significantly higher 8-year PFS, 79.9% vs. 58.2% (P<0.0001), and OS, 87.5 vs. 67.9% (P<0.0001), for mIPI 0-1 vs. mIPI >1, respectively....PFS and OS for patients with stage I-II DLBCL were excellent following rituximab-chemotherapy with or without RT for those who were low risk (mIPI 0-1).

CONTRADICTING EVIDENCE:...152 primary DLBCL patients treated with R-CHOP or R-CHOP-like regimen....Co-occurring MYC and BCL2/BCL6 translocations (Double hit lymphomas, DHL) were recognized in 5.6% cases, most of which were GCB DLBCLs with poor outcome (Figure 1D).